GSK welcomes the National Immunisation Strategy 2025-2030
The new Strategy is an opportunity to maximise the health and economic benefits of immunisation
- GSK calls on the Government to strengthen priorities outlined in the Strategy by recognising the funding of vaccines to prevent disease as an investment.
- Australia’s National Immunisation Program is globally recognised but significant gaps remain.
- The Government has an opportunity to deliver $1.1 billion in benefits every year by increasing investment in adult immunisation.1
David Pullar, Director of Communications, Government Affairs and Market Access, says “GSK Australia supports the Priority Areas outlined in the new National Immunisation Strategy and applauds the Government for recognising the need for targeted solutions developed in partnership to tackle barriers to vaccination.”
“Immunisation in Australia and the National Immunisation Program (NIP) have been a success story, however recent declines in coverage rates for childhood vaccines and the re-emergence of diseases like measles illustrate we cannot take this success for granted.”
“This new Strategy provides a framework for Australia’s immunisation focus for the years ahead. This includes increased recognition of the importance of boosting access to vaccines for Australians throughout life,” says David Pullar.
A recent report commissioned by GSK found that increasing investment in adult immunisation has the potential to deliver $1.1 billion in benefits every year. The report highlights that every dollar invested to vaccinate adults against common illnesses provides a $3.50 economic return. This value is realised through decreased pressure on healthcare systems, government services and carers, while boosting workplace productivity and economic participation.1
GSK looks forward to partnering with Government in the implementation of the new National Immunisation Strategy, boosting vaccine confidence and delivering equitable access to the vaccines Australians need, when and where they need them.
Improving the accessibility and integration of immunisation data will be vital for driving accountability and fostering quality improvements across the healthcare system. Greater investment in preventive health is both economically and medically advantageous, particularly given Australia's underinvestment in this area relative to other countries, such as England and Canada.1
At GSK, we recognise vaccines as a critical investment in health and productivity. By reducing demands on healthcare systems, vaccines bring significant benefits to communities and the economy alike. The Strategy presents an opportunity to align immunisation priorities with broader government policies, including the Health Technology Assessment (HTA) Review and the Wellbeing Budget.
GSK Australia looks forward to continued collaboration with the Department of Health and Aged Care, governments, health professionals, and communities to ensure the success of the National Immunisation Strategy 2025-2030.
Media Contact:
Helena Sfelagis
Senior Communications Manager
0478 261 568
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.au
References:
- 2024. Prevention: A Productivity Superpower - The economic value of adult vaccination in Australia. Available at https://au.gsk.com/en-au/responsibility/our-policy-advocacy/vaccine-access-reports/prevention-a-productivity-superpower/
